ClinicalTrials.govrestricted
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission
ClinicalTrials.gov study NCT03070093. IPD Sharing: Not stated. Countries: 3. Publications: 0.
ShareScore
20/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 8
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4